Aclaris Therapeutics, Inc. (ACRS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US00461U1051
Aclaris Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 7.83 m USD |
| Gross profit | 5.74 m USD |
| Operating income | -76.38 m USD |
| EBIT | -72.56 m USD |
| Net income | -64.92 m USD |
| Diluted EPS – continuing operations | -0.53 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
More stocks
- Centrotec Se (CEV.HM)
- Hangzhou Minsheng Healthcare Co Ltd (301507.SZ)
- GIGAVIS LTD (PROPOSED) (420770.KQ)
- Chong Kun Dang Pharmaceutical (185750.KS)
- Shanghai Shuixing Home Textile Co Ltd Class A (603365.SS)
- Hangzhou AGS MedTech Co. Ltd. A (688581.SS)
- Mengtian Home Group Inc. (603216.SS)
- Beijing ZznodeTechnologies Co Ltd (003007.SZ)
- Mensch und Maschine Software (MUM.DE)
- FIRST BUSINESS FINANCIAL SERVICES, INC. (FBIZ)
- Henan Tong-Da Cable Co Ltd (002560.SZ)
- Unusual Machines, Inc. (UMAC)
Not investment advice. All data without warranty, price as of 05.11.2026. Details in the risk notice.